Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14189644 | 0.83 | MAPT (0.40) | MAPTATMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5029491 | 0.81 | MAPT (0.47) | MAPTATMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23706766 | 0.80 | MAPT (0.48) | MAPTATMSLC6A3ADRA2AADRA2B | |
| SCHEMBL23706772 | 0.76 | MAPT (0.52) | MAPTATMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL828920 | 0.72 | CHRM1 (0.52) | ADRA2AADRA2BCHRM1 | |
| SCHEMBL1327385 | 0.72 | CHRM1 (0.52) | HTR4ADRA2AADRA2BADRA2CMEN1 | |
| SCHEMBL2211491 | 0.72 | — | — | |
| SCHEMBL23706754 | 0.72 | MAPT (0.55) | MAPTATMKCNH2HTR4ADRA2A | |
| SCHEMBL1479904 | 0.72 | GNAI3 (0.50) | HTR4ADRA2AADRA2BKMT2ACHRM1 | |
| SCHEMBL13999390 | 0.71 | HRH3 (0.39) | MAPTKCNH2HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670474-A4 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7317013-B2 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317013-B2 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317013-B2 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1670474-A2 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1656096-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | Parion Sciences, Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005034847-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | PARION SCIENCES, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050059676-A1 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005016879-A2 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | HCN4, KCNH2, CACNA1B | MAPT 3482/4885ATM 4854/4885SLC6A2 187/4885 |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | MAPT 3864/4885ATM 4458/4885SLC6A2 117/4885 |
| US-20050059676-A1 | Cyclic pyrazinoylguanidine sodium channel blockers | HCN4, KCNH2, CACNA1B | MAPT 3482/4885ATM 4854/4885SLC6A2 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.